

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-20 (Canceled)

Claim 21 (New) A method of inducing an antigen specific cytotoxic T cell response comprising administering an antibody, or binding fragment thereof, that binds to CD40 on human antigen presenting cells (APC) without blocking binding of CD40L to CD40, wherein the antibody is capable of inducing an APC-mediated antigen specific human cytotoxic T lymphocyte response.

B7
Claim 22 (New) The method of claims 21, wherein the antigen presenting cell is a monocyte derived dendritic cell.

Claim 23 (New) The method of claims 21, wherein the antibody is a monoclonal antibody or binding fragment thereof.

Claim 24 (New) The method of claims 21, wherein the monoclonal antibody is a chimeric, humanized, human, DEIMMUNISED™, or a single chain antibody.

Claim 25 (New) The method of claims 21, wherein the antibody is a bispecific antibody.

Claim 26 (New) The method of claim 25, wherein the bispecific antibody comprises a binding specificity for each of two different epitopes on CD40.

Claim 27 (New) The method of claim 25, wherein the bispecific antibody comprises a binding specificity for CD40 and a T cell determinant.

B7
Con't
Claim 28 (New) The method of claim 27, wherein the T cell determinant is selected from the group consisting of 4-1BB and CD28.

Claim 29 (New) The method of claim 21, further comprising administering IFN- γ .

Claim 30 (New) The method of claim 21, wherein the agonist anti-CD40 antibody is administered by injection.
